TW200503678A - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
TW200503678A
TW200503678A TW093116599A TW93116599A TW200503678A TW 200503678 A TW200503678 A TW 200503678A TW 093116599 A TW093116599 A TW 093116599A TW 93116599 A TW93116599 A TW 93116599A TW 200503678 A TW200503678 A TW 200503678A
Authority
TW
Taiwan
Prior art keywords
therapeutic agents
oxoethoxy
phenylethyl
ethoxy
hexyl
Prior art date
Application number
TW093116599A
Other languages
English (en)
Inventor
Ralf Ragnar
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200503678A publication Critical patent/TW200503678A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093116599A 2003-06-18 2004-06-09 Therapeutic agents TW200503678A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314136.3A GB0314136D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
TW200503678A true TW200503678A (en) 2005-02-01

Family

ID=27636795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093116599A TW200503678A (en) 2003-06-18 2004-06-09 Therapeutic agents

Country Status (21)

Country Link
US (1) US20060194879A1 (zh)
EP (1) EP1638921A1 (zh)
JP (1) JP3836498B1 (zh)
KR (1) KR20060017646A (zh)
CN (1) CN1805922A (zh)
AR (1) AR044802A1 (zh)
AU (1) AU2004247611A1 (zh)
BR (1) BRPI0411455A (zh)
CA (1) CA2527608A1 (zh)
CO (1) CO5650229A2 (zh)
GB (1) GB0314136D0 (zh)
IL (1) IL172168A0 (zh)
IS (1) IS8232A (zh)
MX (1) MXPA05013713A (zh)
NO (1) NO20055923L (zh)
RU (1) RU2005138369A (zh)
SA (1) SA04250170B1 (zh)
TW (1) TW200503678A (zh)
UY (1) UY28371A1 (zh)
WO (1) WO2004110985A1 (zh)
ZA (1) ZA200510199B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
ATE386013T1 (de) 2002-06-20 2008-03-15 Astrazeneca Ab Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PE20081463A1 (es) * 2006-10-20 2008-10-18 Janssen Pharmaceutica Nv Formas salinas de compuestos de benzotienilo sustituido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1167357A4 (en) * 1999-04-06 2002-06-05 Sankyo Co ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
EP1638921A1 (en) 2006-03-29
WO2004110985A1 (en) 2004-12-23
RU2005138369A (ru) 2007-07-27
UY28371A1 (es) 2005-01-31
AR044802A1 (es) 2005-10-05
CO5650229A2 (es) 2006-06-30
GB0314136D0 (en) 2003-07-23
US20060194879A1 (en) 2006-08-31
AU2004247611A1 (en) 2004-12-23
JP3836498B1 (ja) 2006-10-25
BRPI0411455A (pt) 2006-07-18
KR20060017646A (ko) 2006-02-24
ZA200510199B (en) 2006-12-27
NO20055923L (no) 2006-01-06
MXPA05013713A (es) 2006-06-27
JP2006527767A (ja) 2006-12-07
IS8232A (is) 2006-01-13
CA2527608A1 (en) 2004-12-23
CN1805922A (zh) 2006-07-19
IL172168A0 (en) 2009-02-11
SA04250170B1 (ar) 2007-10-29

Similar Documents

Publication Publication Date Title
NO20055923L (no) Farmasoytisk anvendbare salter av karboksylsyrderivater
MX2007004763A (es) Acidos carboxilicos (bifenilo) y derivados de los mismos.
AU2003238007A8 (en) Methods of treating alzheimer's disease using aryl alkanoic acid amides
ATE504580T1 (de) Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
ATE406863T1 (de) Dentalzusammensetzungen und verfahren mit arylsulfinatsalzen
JP2008510815A5 (ja) プラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）調節剤としてのオキサゾロ−ナフチル酸
MY148953A (en) Substituted biphenyl carboxylic acids and derivatives thereof
SG160217A1 (en) Lactate containing pharmaceutical composition and uses thereof
ZA200708835B (en) Age inhibitors
SV2010003770A (es) Composicion y proceso- 356
PL362366A1 (en) New method of industrial synthesis of tetra esters of 5-[bis(carboxyl methyl)amino]-3 -karboxymethyl-4-cyano-2-tio phenokarboxylic acid, method of manufacture of divalent salts of ranelic acid and their hydrates, as well as new intermediate compounds
TW200503677A (en) Therapeutic agents
TNSN07228A1 (en) Manufacture process of organic compounds
AU2003207467A8 (en) Crystallization of amino acids using ultrasonic agitation
RS63804A (en) Stable salts of o-acetylsalicylic acid containing basic amino acids ii
UA94955C2 (en) Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl] benzoic acid
TW200635880A (en) Manufacture process of organic compounds
MXPA05010398A (es) Nuevo metodo para la sintesis del acido (2s)-indolin-2-carboxilico y aplicacion de mismo en la sintesis del perindopril.
AR027754A1 (es) Nuevo procedimiento para la sintesis de esteres de n-[(s)-1-carboxibutil]-(s)-alanina y aplicacion en la sintesis de perindopril
FR2868702B1 (fr) Utilisation d'une base sphingoide associee a l'acide nicotinique ou un amide de l'acide nicotinique a titre d'agent depigmentant
HK1044957B (zh) 二肽基肽酶i的機械定向抑制劑的醫藥應用
ITMI20042231A1 (it) Cefdinir sale d'ammonio in forma cristallina
DE60218485D1 (de) Auflösungshemmende mittel zur herstellung von gereinigten solen
EA200600230A1 (ru) Способ получения хирально чистого n-(транс-4-изопропилциклогексилкарбонил)-d-фенилаланина и его кристаллических модификаций
TW200635879A (en) Pharmaceutically useful salts of carboxylic acid derivates